Spark Gets A Check From Pfizer And A Downgrade From Vetr

The Vetr crowd downgraded their rating for Spark Therapeutics Inc ONCE on Thursday, from 4.5 stars (Strong Buy), issued 519 days ago, to 4 stars (Buy). Crowd sentiment for Spark is primarily positive, with 80 percent of Vetr user rating bullish.

The genetic research company gained traction when it announced it would be receiving $15 million from Pfizer Inc. PFE after completing a successful safety and efficacy profile of a potential hemophilia therapy.

Responding to this news, share price in the stock shot up nearly $10 to peak just shy of the $60 mark. Spark ended the January 5 trading day a little lower at $58.68.

See how crowdourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Spark Therapeutics is up at $62.50, which is higher than the average analyst target price of $59.68. Less than 2 percent of Vetr users are holding ONCE in their watch lists.